Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Archives of Gerontology and Geriatrics

Volumn 50, Issue 3, 2010, Pages 295-299

  Kasuya, Masashi ^a   Meguro, Kenichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Clinical Dementia Rating 0.5; Cost utility analysis; Donepezil; Mild cognitive impairment; Quality adjusted life years

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; DRUG COST; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; SIMULATION;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; INDANS; JAPAN; MARKOV CHAINS; PIPERIDINES; PRESCRIPTION FEES; QUALITY-ADJUSTED LIFE YEARS;

EID: 77649192580     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2009.04.014     Document Type: Article

References (37)

1. Bhasin M., Rowan E., Edwards K., and McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int. J. Geriatr. Psychiatr. 22 (2007) 890-895
2. Burns A., Russell E., and Page S. New drugs for Alzheimer's disease. Br. J. Psychiatr. 174 (1999) 476-479
3. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., Edwards S., Hardyman W., Raftery J., Crome P., Lendon C., Shaw H., and Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 363 (2004) 2105-2115
4. Fagnani F., Lafuma A., Pechevis M., Riqaud A.S., Traykov L., Seux M.L., and Forette F. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement. Geriatr. Cogn. Disord. 17 (2004) 5-13
5. Feeny D., Furlong W., Torrance G.W., Goldsmith C.H., Zhu Z., DePauw S., Denton M., and Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med. Care 40 (2002) 113-128
6. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., and Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
7. Folstein M.F., Folstein S.E., and McHugh P.R. 'Mini-mental State'; a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
8. Gauthier S., Feldman H., Hecker J., Vellas B., Ames D., Subbiah P., Whalen E., and Emir B. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr. 14 (2002) 389-404
9. Gauthier S., Feldman H., Hecker J., Vellas B., Emir B., and Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr. Med. Res. Opin. 18 (2002) 347-354
10. Geldmacher D.S., Provenzano G., McRae T., Mastey V., and Ieni J.R. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 51 (2003) 937-944
11. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in Health and Medicine (1996), Oxford University Press, New York
12. Holmes C., Wilkinson D., Dean C., Vethanayagam S., Olivieri S., Langley A., Pandita-Gunawardena N.D., Hoqq F., Clare C., and Damms J. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63 (2004) 214-219
13. Homma A., Takeda M., Imai Y., Udaka F., Hasegawa K., Kameyama M., and Nishimura T. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement. Geriatr. Cogn. Disord. 11 (2000) 299-313
14. Ikeda S., Yamada Y., and Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement. Geriatr. Cogn. Disord. 13 (2002) 33-39
15. Krall W.J., Sramek J.J., and Cutler N.R. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann. Pharmacother. 33 (1999) 441-450
16. Meguro K., Ishii H., Yamaguchi S., Ishizaki J., Shimada M., Sato M., Hashimoto R., Meguro M., and Yamadori A. Prevalence of dementia and dementing diseases in Japan: the Tajiri project. Arch. Neurol. 59 (2002) 1109-1114
17. Meguro K., Ishii H., Yamaguchi S., Ishizaki J., Sato M., Hashimoto R., Meguro M., Lee E., Tanaka Y., and Kasuya M. Prevalence and cognitive performances of Clinical Dementia Rating 0.5 and mild cognitive impairment in Japan: The Tajiri Project. Alzheimer Dis. Assoc. Disord. 18 (2004) 3-10
18. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., and Perdomo C.A. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
19. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., Mellits E.D., and Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989) 1159-1165
20. Nakata E., Kasai M., Okazaki M., Yamaguchi S., and Meguro K. Combined brief neuropsychological screening tests of memory, orientation, and executive function can screen MCI subjects in a community: The Osaki-Tajiri Project (1). Int. Psychogeriatr. 19 Suppl. 1 (2007) 372
21. Neumann P.J., Hermann R.C., Kuntz K.M., Araki S.S., Duff S.B., Leon J., Berenbaum P.A., Goldman P.A., Williams L.W., and Weinstein M.C. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52 (1999) 1138-1145
22. Nochi S., Asakawa N., and Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol. Pharmacol. Bull. 18 (1995) 1145-1147
23. O'Brien B.J., Goeree R., Hux M., Iskedjian M., Blackhouse G., Gagnon M., and Gauthier S. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J. Am. Geriatr. Soc. 47 (1999) 570-578
24. Onofrj M., Thomas A., Iacono D., Luciano A.L., and Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin. Neuropharmacol. 26 (2003) 239-251
25. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999) 303-308
26. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
27. Petersen R.C., Thomas R.G., Grundman M., Benett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levery A., Pfeiffer E., Sano M., van Dyck C.H., and Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Eng. J. Med. 352 (2005) 2379-2388
28. Purandare N., Swarbrick C., Fischer A., and Burns A. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England. Int. J. Geriatr. Psychiatr. 21 (2006) 961-964
29. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., and Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
30. Rogers S.L., Doody R.S., Pratt R.D., and Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol. 10 (2000) 195-203
31. Salloway S., Ferris S., Kluger A., Goldman R., Griesing T., Kumar D., and Richardson S. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63 (2004) 651-657
32. Seltzer B., Zolnouni P., Nunez M., Goldman R., Kumar D., Ieni J., and Richardson S. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch. Neurol. 61 (2004) 1852-1856
33. Tombaugh T.N., and McIntyre N.J. The Mini-mental State Examination: a comprehensive review. J. Am. Geriatr. Soc. 40 (1992) 922-935
34. Torrance G.W., Furlong W., Feeny D., and Boyle M. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 7 (1995) 503-520
35. Wimo A., Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wetterholm A.L., Mastey V., Haglund A., Zhang R., Miceli R., Chin W., and Subbiah P. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord. 15 (2003) 44-54
36. Wimo A., Winblad B., Shah S.N., Chin W., Zhang R., and McRae T. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr. Med. Res. Opin. 20 (2004) 1221-1225
37. Winblad B., Engedal K., Soininen H., Verhey F., Waldmar G., Wimo A., Wetterholm A.L., Zhang R., Haglund A., and Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495